Medexus Pharmaceuticals Inc. (TSE:MDP – Get Rating) shares were up 14.3% on Wednesday . The company traded as high as C$1.24 and last traded at C$1.20. Approximately 121,771 shares were traded during mid-day trading, an increase of 367% from the average daily volume of 26,103 shares. The stock had previously closed at C$1.05.
Analysts Set New Price Targets
Separately, Bloom Burton downgraded shares of Medexus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday.
Medexus Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 327.43, a quick ratio of 0.44 and a current ratio of 0.97. The firm has a market cap of C$21.95 million and a P/E ratio of 6.88. The firm’s fifty day moving average price is C$2.32 and its 200 day moving average price is C$2.52.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.